KORU Medical Systems (NASDAQ:KRMD) Releases Earnings Results, Hits Estimates

KORU Medical Systems (NASDAQ:KRMD) issued its quarterly earnings data on Wednesday. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02), Zacks reports. The firm had revenue of $11.76 million for the quarter, compared to the consensus estimate of $11.28 million. KORU Medical Systems had a negative net margin of 6.41% and a negative return on equity of 15.90%.

Here are the key takeaways from KORU Medical Systems’ conference call:

• Q1 results beat expectations with $11.8M revenue (+22% YoY), adjusted EBITDA essentially break?even (-$10k) and net loss improving 33% to $0.8M, while cash usage was minimal at $0.1M leaving $8.8M on the balance sheet.
• Management reiterated full?year 2026 guidance of $47.5M–$50M revenue (15%–22% growth), 61%–63% gross margin, and positive adjusted EBITDA and cash flow, and retains access to a $10M debt facility.
• International expansion showed strong traction (international core +35%) driven by EU prefilled?syringe conversions and distributor pump orders, supported by Freedom60 MDR clearance for prefilled syringe compatibility.
• The non?IG pipeline advanced—now eight active non?IG opportunities (>6M potential annual infusions), two pharma partners moved into phase III (including Apellis EMPAVELI in DGF), and a 510(k) was submitted for deferoxamine, while vancomycin was deprioritized.
• Q1 gross margin compressed to 61.5% (down 130 bps) due to production timing and tariff charges, although management says adjusted margins and cost initiatives keep full?year margin guidance intact.

KORU Medical Systems Price Performance

Shares of NASDAQ KRMD traded down $0.07 during trading on Wednesday, reaching $4.01. 151,549 shares of the stock traded hands, compared to its average volume of 138,622. The company has a 50-day moving average of $4.34 and a 200-day moving average of $4.85. The stock has a market capitalization of $186.91 million, a P/E ratio of -66.83 and a beta of 0.43. KORU Medical Systems has a 52-week low of $2.63 and a 52-week high of $6.61.

Hedge Funds Weigh In On KORU Medical Systems

Several institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC grew its position in KORU Medical Systems by 927.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 77,280 shares of the company’s stock worth $196,000 after acquiring an additional 69,758 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of KORU Medical Systems by 189.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock worth $617,000 after purchasing an additional 158,914 shares in the last quarter. Jane Street Group LLC grew its stake in shares of KORU Medical Systems by 136.7% in the first quarter. Jane Street Group LLC now owns 163,137 shares of the company’s stock worth $414,000 after acquiring an additional 94,214 shares during the period. Acadian Asset Management LLC bought a new stake in shares of KORU Medical Systems in the first quarter worth $63,000. Finally, Geode Capital Management LLC grew its holdings in shares of KORU Medical Systems by 101.3% in the second quarter. Geode Capital Management LLC now owns 997,147 shares of the company’s stock worth $3,571,000 after acquiring an additional 501,875 shares during the period. 58.60% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on KRMD shares. Wall Street Zen cut shares of KORU Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. B. Riley Financial raised their target price on shares of KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Craig Hallum reissued a “buy” rating and issued a $7.00 price objective on shares of KORU Medical Systems in a report on Tuesday, January 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $6.00 price objective on shares of KORU Medical Systems in a research report on Friday, March 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Tuesday, April 21st. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.50.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.